6/30/2022 6:39:14 AM
Codiak BioSciences Announces Platform-validating Clinical Data From Phase 1 Trials Of ExoSTING And ExoIL-12
3/11/2022 4:51:08 PM
Wedbush Is Cutting Codiak BioSciences, Inc. (CDAK) FY22 Estimate To -2.40 From -1.85
3/11/2022 4:50:50 PM
Wedbush Is Cutting Codiak BioSciences, Inc. (CDAK) Q4 22 Estimate To -0.42 From -0.40
3/11/2022 4:50:38 PM
Wedbush Is Cutting Codiak BioSciences, Inc. (CDAK) Q3 22 Estimate To -0.42 From -0.38
3/11/2022 4:50:23 PM
Wedbush Is Lowering Codiak BioSciences, Inc. (CDAK) Q2 22 Estimate To -1.07 From -0.40
3/11/2022 4:50:06 PM
Wedbush Is Lowering Codiak BioSciences, Inc. (CDAK) Q1 22 Estimate To -1.06 From -1.00
3/11/2022 4:49:32 PM
Wedbush Reiterates Codiak BioSciences, Inc. (CDAK) At Outperform With $24 Price Target
2/22/2022 5:00:34 PM
Wedbush Is Increasing Codiak BioSciences, Inc. (CDAK) FY22 Estimate To -1.85 From -3.17
2/22/2022 5:00:19 PM
Wedbush Is Raising Codiak BioSciences, Inc. (CDAK) Q4 22 Estimate To -0.40 From -0.81
2/22/2022 4:59:38 PM
Wedbush Is Raising Codiak BioSciences, Inc. (CDAK) Q3 22 Estimate To -0.38 From -0.79
2/22/2022 4:59:27 PM
Wedbush Is Increasing Codiak BioSciences, Inc. (CDAK) Q2 22 Estimate To -0.40 From -0.79
2/22/2022 4:59:15 PM
Wedbush Is Cutting Codiak BioSciences, Inc. (CDAK) Q1 22 Estimate To -1.00 From -0.79
2/22/2022 4:58:24 PM
Wedbush Reiterates Codiak BioSciences, Inc. (CDAK) At Outperform With $24 Down From $34 Price Target
5/19/2021 9:45:37 AM
Invaio Sciences Announces Agreement With Fundecitrus In Brazil To Combat Against Citrus Greening
3/17/2021 7:38:28 AM
Codiak BioSciences Q4 Loss Per Share $1.14 Vs Loss $8.37 Last Year